{"denoms":[{"counts":[{"groupId":"BG000","value":"102"}],"units":"Participants"}],"groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"BG000","title":"Brentuximab Vedotin"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"15","upperLimit":"77","value":"31.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"48"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"89"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42"}]}],"title":"0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"60"}]}],"title":"1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"2-5"}],"description":"0 = Normal activity\n\n1. = Symptoms but ambulatory\n2. = In bed \\<50% of the time\n3. = In bed \\>50% of the time\n4. = 100% bedridden\n5. = Dead","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group Performance Status","unitOfMeasure":"participants"}]}